NERV - Earnings call transcript Q2 2020 | Minerva Neurosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Minerva Neurosciences Second Quarter 2020 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session, following today's prepared remarks. The call is being webcast live on the Investors section of Minerva's website at, ir.minervaneurosciences.com.

As a reminder, today's call is being recorded. to of call Communications Investor like Boni, to at now President Vice Relations would turn over the William Minerva. I and Corporate proceed. Please

William Boni

morning. Investors A.M. Eastern quarter today, company's and business with found press our Time became financial on website. be the highlights X:XX results and of Good second at available can A section release XXXX the

at also morning, Our quarterly the www.sec.gov. Commission the this and Securities be with SEC's report on website filed Form and electronically XX-Q on can was found Exchange

the Mr. Joining Minerva Chief Dr. Executive on Business from me call Chief are Chief President, Remy today and Officer. Chairman Executive Vice Financial and Luthringer, Geoff Executive Officer, Officer; and Race,

the Following for Q&A. our remarks prepared will open call we

reflect or today's these obligation include subject over to XXXX uncertainties disclaims current due June expectations that of statements speak including circumstances indicated. variety forward-looking detailed and made X, caution under differ under that ended the X, the call expectations, filed as SEC report these I plans, company forward-looking are this that a our the of on only Luthringer. XXXX Harbor These the quarterly Litigation our future like constitute statements by Reform on call turn to August SEC, those about we fully I Form factors Act Any required XXXX. you to Before begin, will forward-looking as from except any would Monday, today's more after filings Factors on for XXXX. law. actual based company's to prospects in the caption materially statements for like on would quarter risks Private are to update Securities XX, provisions Risk forward-looking with from of date Safe Remy cause We the statements that with forward-looking occur XX-Q any discussion the of actual purposes events statements the of remind that that and to materially call our and to are statements differ now to August results results the may and may today's

Remy Luthringer

than from XX study XXX huge roluperidone, carried first Today, data Phase doses of milligram Thank I I I were in treatment believe XX the doing primarily with everyone. lead and negative compiled recently opt The in morning focus of joining of weeks. the on everyone symptoms and Israel. Today, which from was product, over X symptoms begin why as decision you, blind main and agreement schizophrenia continue the Janssen with specifically. the on More well. the of from on With discuss a on data to evaluated additional an well patients, program giving schizophrenia. the and symptoms trial. have seltorexant good with Xb of years, unmet to After Phase treatment The Thanks that in review completed the the sites builds directly to the is roluperidone. us. co-development Phase our I negative Today, will potential will has over is is improve Based roluperidone task Minerva’s the for on X places there data, the reason to the patients hope clinical health and U.S., medical two trial Pharmaceutics. be would trial roluperidone Europe, update on out about update drug also the families, States. the double suffer United Phase Bill and patients care as included like trial out XX it in an burden we the a of roluperidone approved need a recent suffering we and patients in XX data for significant to which for in system. negative diminished X review function no milligram

Following to than additional XX extension that months Phase and the the XXX This either of milligram. now treatment on XX patients with week or were patients nine I'm roluperidone entered extension report period completed XX offered a double an patients the had report blind pleased dropped be over patients study XXX continues more the a result nine to date pleased in observed positive I'm overall the to the of months also number only extension. one worsening year very as of of treatment period. out that of limited symptoms. to

as was achieved improvement compared Xb. high X in the schizophrenia well XX. score primary end why also roluperidone Steve we Statistically the not score Functional week observed Phase this what significance showed XX performance at far. was proposed by trial statistical both week negative doses Those superior statistically with significant So and was a believe as of value and all significantly symptoms Phase the about at XX. be Marder or factor differences week improvement have negative placebo were in placebo between NSFS, might at milligram groups measured eight point to from We P doses with so trial weeks the personal treatment week four this NSFS placebo week the and nominal extracted from scale learned as active and by XX X.XXX active numerically mg with assessed social improvements PSP to timescale dose XX the only. in superior in receiving

is of interest by functional level avolition patient's behind the at or consequently core directed behavior. largely And looking lack or of We symptoms. improvement the and explore meaningful to continue components driven the suspect of negative the in negative goal engagement in of symptoms this improvement improvement by drivers we it

for our additional for of So and I be with of we the our seltorexant. analysis path of announced to will the would now out discuss we next data July X clinical Phase a to program the we development. On Janssen right to MIN-XXX. development forward that complete like exercise is stage opt second we FDA once address with the what agreement data the XXXX roluperidone’s our meeting seltorexant X, requesting our package

worldwide single-digits of forward. program all program. financial payments obligations at the decision the collect retain [indiscernible] interest and led the of a As agreement the significant the new with with stream this to same result The moving with large significant royalty make in financial out obligation to financial us sales a Janssen of stage revenue to no to Stage opt Minerva At mid seltorexant future will full indications. remains to potential in of time [indiscernible] it fund X commercial indications, company’s

receive primary out is help align roluperidone opt to of enable effective Our human resources focus and lead compound to approval patients our for no currently us to decision which our financial source and to with will our treatment. there

would negative of a turn data updates conviction opportunity innovative schizophrenia families financial roluperidone based Before an that profile will accumulated Geoff their it to on handing past to symptoms. This us and conviction mechanism of Phase encouraging has data over important effectively is and combined roluperidone. and our had to the beyond. the the now commercial be with potential approved potential over with years. negative that significant we roluperidone like Geoff. gives of in you our the restate give data to growing combined symptoms The [ph] drug symptoms over to understanding program confidence to remains treat of the significant the X we few first in safety with action and the and goal I of The to future benefits treat an patients table negative recent

Geoff Race

our our for XXXX million. equivalents, operating reports presently will Remy. issued equivalents the into capital A cash, evaluated cash were operating quarter company’s quarter press with results million this approximately its on plan. the were is million XXXX second may of and our $XX.X routinely the upon results release to estimate second in assumptions summarizing meet anticipated in existing a which to morning early discussion subject requirements We XXXX. that XX-Q expect this found Thank June be current Cash, of development XXXX the and compared $X.X today. be and XX, sufficient and XX, our Research XXXX. detailed change. on may be based we restricted The Earlier for quarter are second the of securities earlier to expenses marketable $X.X quarterly in ended based cash you June as filed Form SEC cash more

$XX.X For to lower and the Phase the XX, XXXX. million clinical expenses trial six ended to during months six months trial expenses X development clinical June Xb ended primarily $XX.X the million June roluperidone reflects XX, compared of for R&D the and expenses XX, the months XXXX in XXXX decreases were R&D of ended June MIN-XXX. Phase quarter six The

trial clinical second and were in the to decrease quarter during of MIN-XXX double-blind administrative expenses quarter as and compared of portion the General R&D $X.X second trial to Phase completed expect $X.X we of the in X million We have the XX-week XXXX roluperidone. million the XXXX. expenses clinical XXXX

a basic and months six quarter $X.XX months June net of in and six $X.XX basic $XX.X of income the expenses for to of ended $XX.X million per Net net in or increases and were XXXX. XXXX loss increases XXXX diluted and stock million basic net of diluted a For ended months was diluted based $X.XX XXXX. to XXXX. loss $X.X the million of for compensation in G&A the quarter the per as quarter the respectively XX, million $X.XX million share share compared compared to and The and as period $X.XX Net per share benefits. expenses for same due of loss million net severance first second months first the income for or $XX.X compared loss XXXX per second income $XX.X non-cash six a during G&A of $X.XX to and six a share June XX, primarily were or the basic of $XX.X diluted for expenses income respectively was or of XXXX and

the with in the deferred the included of the products during collaborative in in any As Janssen the and revenue. date This of given million been have which revenue out a future million The had expenses obligations royalty the opting recognize of agreement. the $XX.X amendment. were made the will by amount not recognized revenues under company to agreement Janssen quarter effective balance previously Janssen, under million upon future related XXXX represents payment sheet previously and agreement periods collaborative company XXXX, any of of of by sale on $XX.X $XX second in the the accrued performance result the does

operator like the turn the to any I'd call Operator. to questions. Now, over for

Operator

[Operator Instructions].

comes question from Citi. first Our Joel with Beatty

Shawn Egan

Hi, to for my why program, seltorexant for plans the decision this you you provide Shawn a questions. me develop still Maybe Egan right I A taking to on that this color a was time question then of as more Joel. think little decision you forward? whether can few the and today. up on have the follow Thank on your at effort bit for going roluperidone calling out is any well. in Janssen opt And

Remy Luthringer

the thank question. So It is for Remy you speaking.

So is I think this of molecule who we molecule I interesting is which I molecule, molecule, cannot really going really that [indiscernible]. and speak clearly, But need a forward. important very mean, And is a patients hope moving treatment. this very this think a kind is obviously this really project I to

part the For take maybe out. can why the opted Geoff first we it, question, of you

Geoff Race

out that with part of Yeah, program. its really based rate rights earlier program in investment And the Remy better of benefits and on the that the make for as opt looking the and of decision as we royalty X in a agreement the was return we The shareholders updates was had his described Minerva would today. We have decision. it thanks return Shawn. the to program, we and a Phase for investment were take compared opt our to that European the the the this felt smaller out royalty at to of size by question, Janssen to on

Shawn Egan

for to that publication, Perfect, is you kind the when and data metrics most And to thank share details X I how data are of of do Phase zeroing on? you. what important presented on of kind additional investors when then roluperidone, be guess the plan the

Remy Luthringer

great question a getting it's obviously and often. question are a quite it's So we

Phase additional what mean, that, Clearly, this talk about if So to is I all did of this have hand my in we I I my have avolition the analysis. lot analysis I before, alluded say this Gregory I the not how as of the in the are Remember, functioning XX, in a improvement I that, is analysis just driver all patients And mean, translates to and showing it, of and week fitting we even the that at hit we like that really the can additional data doing had from the before. avolition a was the is P improve symptoms. consequence of key showing as PSP patients. done a also are functional the a all we are avolition at Xb value to Strauss and mean, it's improvement clear into in day negative hinted end really improvement this the a really driver. the had together is fitting publication of really all together. we overall

to Now complete will with and are is for all the with a most think be give do the the know ready I important don't we that I FDA. this, update you but really details, we when the preparing meeting

It's together. I data all a is now in to think this all convinced a and the the not data FDA. most you sites request the a highly is us, which to we that coming Yes, is So that than in or what if had have matter tune give the we a X obviously line higher. outcome submit the the had to in and fine do. the more this to the from effect the patients Phase as meeting bottom the now the moment because even think Phase doing next caregiver the that drug the Phase It's study best the basically of placebo, for important clear minutes days and are have on Xb we more Xb, expectation update and the because or you more was but is it have of this surprise to the I from PIs, we positive will

the from obviously And to XX action, So and sites FDA. to coming, good that has you're will to looking consequences functional a when an from this an avolition that again, confident also is I'm went sites. meeting the is drug, explanation. the have innovative very We effect the where obviously overall, one with XX of we with impact mechanism this

I as is this what and of can So where tell are we you today.

Shawn Egan

That’s it, much. very thank you

Operator

comes question with Amin Biren next Our from Jeffries.

Unidentified Analyst

I our meeting Any guys. willing going Biren. the second, for us feedback any this is when you're do the Yes, take be the FDA idea you'll hoc of accept place with when post with on and Thanks for FDA the come the the space Thank good scheduling to looks Maybe you. back data Remy. guess in accepting two you perhaps believe in Jeet data meeting next are from hand? analysis be may for to This regulatory just in FDA And questions. morning days. might that neuropsych it taking like approval? and there examples of such couple

Remy Luthringer

days, meeting will the obviously we I the XX time soon, if timing us. or will usually. the was depending on there mean, for case submit meeting concerning document be get the a to a So you very ask of is which type XX granted

the sorry. meeting this, we say to how or month And have -- quarter as feedback last get will the a end of one of the later. we third definitely quarter So, might feedback during

So the and month later. third meeting feedback one quarter

impact don't So FDA is is on what the been responsive what track meetings things the on a I COVID know this heard perfect FDA of respecting the that I and as are life. minimum timetable. but is the the has

the have minutes. in meeting we So again and when afterwards is QX feedback our

placebo on example, concerning in Now Obviously, our to hoc post have I a for your mean, behavior. commodities. we the analysis only question, hoc lot package better order post not think based is I understand, of done [ph]

PSP. quantify, post on have the better hoc example, the in for order We effect some analysis obviously done to

a just which the So the which in improvement of are been before the out did the scheduled about post has obviously PSP before. statistical FDA to and data the hoc analysis driver, symptoms see what speaking is or analysis correlated, -- avolition was some and negative blinds. the submitted the plan, came before analysis we or But I confirming I is opening mean, if to was

our I been the said the are which This done post lot think convince which the absolutely P not I quite are in there will hoc FDA. think green forward package which was CNS hopefully value where of have mean, not examples, light some analysis on I primary given maybe but but move space some the FDA a to there color a hoc some examples So sponsor a giving based have additional to post by in endpoint the we was priori not on and analysis.

our the XX, data. I'm combination hopefully but consider, that pointing of but things enough the the think it all Again fact have This molecule the remember the Phase something not data at are help. will So a But not the two story convince which but to endpoint I extremely the a saying we will in again, will lot we again, not towards I Xb. week that the similar be FDA. rest we think really long have achieved working, the definitely Again, studies. primary of analysis, is priori showed will the short I we

Unidentified Analyst

Appreciate the you. Thank color.

Operator

question next with BTIG. Shrader comes Our Thomas from

Unidentified Analyst

Julian good for Thanks morning. taking is Hi, on Tom. our This for questions.

we First, your study would at other on could likely additional best talk early that's in in you it's expect ultimately study roluperidone still dose differences duration about time? interest, just just any it an be comment look keeping this possibly like Phase can one would a likely X you if for mind and shorter what could and

Remy Luthringer

are we now try I having virtue and a I no life family or patients medical personally unmet beginning are able small this this not the even what dealing address not would is functioning really think important. making get forward in molecule very life these mean, able So has and really is And [ph] really this an need to company a I as with which all, need, is and unmet this moving being any to first to again, getting that and the decent important of that are medical be job obviously which treatment. from

So and can can you repeat that again, I I'm is I your answer. just -- what us you really is right so really sorry driving missed your the give this I question think that

Unidentified Analyst

sure. Yeah,

the after can it's me. you yeah, reconvened [Multiple if Speakers] with perhaps hear So FDA, you yeah,

Remy Luthringer

Yeah.

Unidentified Analyst

like that whether So for best will an one meeting X it Phase things your just whether duration, a a concluded you the it if likely proceed to would is look be additional with most in us recently what one, that might interest study, short dose, can after give to be like sense compared that? it

Remy Luthringer

in wanted say is mean, to what So study or wanted obviously do it's Definitely Phase Yes, that X will the if go what will accumulate I And like because study -- of I heard, terms having are say things we just measurements. we know And you we very to extension. it a study extension. this important one be extension the lot basically that, is going data well with in a terms to of best in always completed we study. no efficacy have to of I would this dose. a be very also in already as some

So an extension. without study be this will a definitely

So one two definitely dose not doses. versus placebo,

explaining that say is started reason I is that So avolition why this is what wanted with is the driver. and to a negative symptoms, I

do primary functioning. obviously what what we way extract is to with is study, and to if calculate discuss best will will a the We a endpoint, negative how we discuss symptoms, do the we FDA, have

did we right the thing. think I

negative is a the is is significant to into and and I Phase subdivided And value clear I only with symptoms well was highly also there. mild is And of is that can sub or avolition experience, mean, expression. as symptoms it a had items we you they this accepted negative today into we experience, it two dimensions, here symptoms A this that the know. part different score that of two a construct. -- think I that be mean, remember course, had is P mean construct it's consensus negative negative

what not really sites, think a they or because well. it be two we smaller will will reduce best X yes, in the the discussion ask scoring change the this I the do we very happens completely maybe best trends of straightforward one would the you have question, there about Phase would much is think control sites to us sites as that be if is to what of primary study this right, a able secondary what I endpoint. were think you brackets done is and study, I what number more the should or change are But in because I But scoring. think a do I much have definitely study. did is mean, we what So sites But

performed have we XX reduce of we sites And number So this the have insight lot we also analysis in of completed sites. how will have sites we study. because the the of participated obviously of a have the

to We analysis have back the Phase of all the also as -- decide who Xb. we went of sort participated had sites to

study because a the have to So thing and treatment. patients the this motivation score symptoms patients successful be placebo will the score the really sites a the the criteria context, but not be discriminating or is a first the of implement by sure of this really this in to separation create the would from to in order right to placebo will will having we that we this make sites from essence really have really

Unidentified Analyst

the Okay, seltorexant, this insomnia disorder in aware have any on? got is on then Cornell insomnia you it. for you depressive market that's very something beyond And broader are time helpful. at development plans last major Thanks, did, that any visibility what of

Remy Luthringer

population, the MDD will who the insomnia insomnia of objectively of I quantified have will X took in [indiscernible] this program a be see trials. addition, will Phase are royalties. Janssen, in also by is included eligibility be depression. these out that I and mean, it's who insomnia driver of we little And it subjectively of and a big going program run in bit during criteria in our patient populations, Keep the because as we beyond know mind characterized and means the the you complained be the patients. as think insomnia the But patients this

or So already in I in think be population. MDD the trials will trial covered which the the insomnia run the with part is

Unidentified Analyst

Okay, great. Thanks very much.

Operator

Instructions]. [Operator

comes next Securities. question JMP Butler from Our with Jason

Jason Butler

taking question. for thanks the Hi,

one data either now priority, wondering Thanks. with how Just me would in hand, other this there more U.S. partnering a Is for or on quick of the or you roluperidone things have think consider just already you any discussions? are started you and for about global territories. it a priorities that in

Remy Luthringer

maybe as minute, to I Jason, mean So will within but I got in past, have give been pharma over bounds I to a the we Geoff companies. in always already discuss discussed think we open from we

are as as you you want a can guess, we completely updates give this. mean, development asked aware of them companies updates obviously to Geoff, have continue the for. color are if But more maybe roluperidone and to done. lot the give we on So I about But pharma know, you

Geoff Race

should additional much There more have add Thanks to we'll to discussion for with provide discussions FDA, that. We'll in which Jason. our really those have at and isn't information to point that the question, time. the partners potential

Jason Butler

you. great. Okay, Thank

Operator

Our Minter comes question William Myles from next Blair. with

Myles Minter

for thanks questions. guys, Hi the

just really as are describing that this reasons in is in why clinical alluded something would the quality formulating to up just that to might difference data you're that's have you there's the with that and just only be whether first the in Phase up, that there Phase differences an ask that about the the sites points else or the any in the is Just had so between you wondering Remy anything the the that coming response is for now, reasons data coming why specific of occurred? time demographics a the wondering the analysis I'm on be additional the it seen differential I this patient one response placebo might color FDA potential a to something have really that argument because that X. the difference, going I obviously Xb little additional to

Remy Luthringer

a you an And mentioning of mean, sites. question. I And we've mean, we some is of as know we lot the happened. quantity I on this and study I patients duration, included the But level characteristics, expectation I in after between terms of think of mean, has of positive data. the who what Yes, I been obviously the two positive changed increasing. in what's great has Yeah, of studies the is mean a can so that studies. in of not stability, symptoms, understanding also I was I terms this have on a negative think negative had worked was the this terms I symptoms some definitely of scoring influence have of guess, clear symptoms, mentioning, Clearly, in definitely in

sites very So study an symptoms, hand, several we is is I have FDA. a sense improved who of has important from the how have study are are are think another obviously which things. back and and we clear it when is during which expectation about that There is hand reports in sites aspect going basically have the we the Again, dramatically of important the work, shown will several patients really which scoring. having an in negative which has influence on to to

see you milligram that sites towards the or of of obviously the XX So recruitment, the the study the that double is end end XX XX that with patients week to improvement the to are course extension, they is willingness was because or patients here push milligram. know of an really, there treated of the of the could the the towards blind during phase the

and demonstrate helpful put our and going have explaining two briefing and to which be the will placebo same the X mg things I the important when lot a what call XX Xb So Phase very a book to particularly is we between studies. obviously really is more the you going inflation will Phase why present most doses you of with the present which are and improvement XX they think the data FDA that what show to this there between this what arm. of with or to the had we is in are the think seen are of and But we something are I

here We PSP, the driver. very, we is avolition know will more demonstrate extremely clear the you the more an things is very go looking that and see And today into important And about at which again we obviously will are have data hand. improvement. to as details are functional you the when also

really is So as when from symptoms been influenced. I mean, the this or these, you extremely and have that the different has of tried the you're into placebo as fitting is to a treatment a together all is dimensions. not I the going definitely And negative well influenced very primary are see from placebo Phase and are X effect construct placebo. pieces before as by more not been details It's positive inflation these aspects coordinating surprise they different endpoint extremely explain the and well because

full So this package will to we the will be FDA. present the

Myles Minter

perspective, withdrawn something on and manage there receptor discontinued just must Maybe from these final That's a or of due relapse. in specific with roluperidone patients one from patients one helpful, small there the they therapy treatment? adaptive blockers just world terms in they study open positive have label go these be symptoms how patients were the that real amount that in me, of extension to

Remy Luthringer

question there a included than handful nothing specific because mind phase the double-blind extension. your really is have I there and that of more in patients there specific, relapsing is to the about a and indicated as is and here think patients handful I'm are in we XXX [ph] coming keep I add-ons in here we who I mean have nothing

antipsychotic whatever not symptoms. you the looking relapsing of and a who have to on when if run have six So generation, I been with mean, period over trials are are trials on you responding your second four antipsychotics run or weeks, the which are first take people to positive

So there's in is of a line we relapses you number antipsychotics. see with really with see what

I symptoms. I So significant data to Europe stay schizophrenia with who to order to show FDA patients need extremely that CH&P of to think diagnostic of amount not in will you or our antipsychotics of do helpful be in mean, absolutely the terms have a positive can stable a in the

on a willing will it and clinical discussed the doses the the psychotics we practice can we who good of time and convince and drug think significantly the prescribed be [ph] quite already them is little are evolving of this bit the of the add-on, add-on as question Now these discussed out U.S. in some have this that have the increase. know there publications Obviously need who our as do in But not take of will I very patients of antipsychotics and antipsychotics. all a you very, amount past not to monotherapy. XXX go showing target in because give field also as will about of we based still and about prescribers we profile, dramatically a in past the significant relapses your you is number to product that review reduce very as some

remember, do think which I story of the as but diagnostic going we together inclusion with that of schizophrenia. XX% represents of hand lot is to this really not exclusion and So XX% data in have a the as relapse the our with again, patients criteria, you're a patients when are showing is coming

schizophrenia. speaking about diagnosis very large not marginal the a patients of the with we're population, a So speaking here but with part of very,

short, you story positive think But when this have So little also I patient again, are cope a able the was ago minimum when time symptoms the functioning, is symptoms It with is because bit hospitalizations/relapses I started a will at of a to improving which probably more number believe long and improving this my you need long, everyday time. life. project, symptoms and a drug little are this negative negative or long will it really functioning. improving bit need we and still And I education. here hypothesis

a molecule having It paradigm a and on effect going a has effects, functioning. which shift. is it's obviously impairing So less which through symptoms is really side negative the which patients, is less specific

a a So into time right here. moving little the it will think the bit I educate to but as take is direction prescriber, really field

Myles Minter

questions. the for Thanks Fantastic.

Remy Luthringer

welcome. are You

Operator

from question Wainwright. with Tsao Douglas next H.C. Our comes

Douglas Tsao

questions. Hi, morning. good for Thanks the taking

prioritizing to treating the some finish sort being, of the Just well future of the of work we of about you terms onset a the of sort How considering across some sort me. in pipeline the you. thinking almost of as are time the sort disease subsequent ability prevent couple sort of you for or or of now that were now -- in the Thank of prioritizing just patients terms in in of is just other the really on for it or resources as, getting assets focusing and roluperidone line?

William Boni

Speakers] line [Multiple your muted Remy. Is

Remy Luthringer

So can you now? hear me

Douglas Tsao

Yeah.

Remy Luthringer

Sorry.

Doug. Sorry

avoid disease, that want to into first or that that are disease, we first because So blown prodromal they do. think symptoms who the have the can if even maybe schizophrenia I full example, going, disease still showing absolutely positive mean, prodromal you have for symptoms. who Yes, psychotic before for they blown the subject this episode might to clearly negative about question might are if negative transform is the symptoms change a all some the have something your patients you patients we you data having have full of example, the I

is done because approval clearly, very a or better subjects in in will which this study. I the right case study but I in But our specific the a this So schizophrenia. study mean something we is earlier working is be this needs think on, and are yes, post also

the the We have plan. outcome other highest have good to the outcome, to FDA. Yes, have start is via priority best roluperidone. the other to here sure to And but make we again outcome assets, according need a concerning that assets priority can on the move very obviously Now the think FDA. based a highest from positive I the with we

on And sorry mute. I was technical about definitely issue. this

Douglas Tsao

no Oh, worry.

Operator

further any this not I'm time. questions showing at And

Remy Luthringer

you Okay, it and for all helpful. hopefully questions was the so thank

have progress update very FDA the will We to update on will the looking the to about key are we we all forward next about made be soon them. major provide event since based us what and the the that you telling data is

Thank So, forward an thank you looking very give again all. soon. you update to and you

Operator

again concludes you this gentlemen, once your Thank participation. for and today’s Ladies presentation.

day. a disconnect and have now great may You

Minerva Neurosciences (NERV) 3 Aug 202020 Q2 Earnings call transcript